{
    "nct_id": "NCT06264180",
    "official_title": "Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment",
    "inclusion_criteria": "* Male or female who is 12 years of age or older at the time of signed informed consent.\n* Patients with histologically or cytologically confirmed unresectable or metastatic Stage IIIb through IV/M1a through M1d cutaneous melanoma.\n* Confirmed disease progression (PD) on an approved anti-PD-1 and an anti-CTLA-4 treatment, administered either as a combination regimen (eg, nivolumab + ipilimumab) or in sequence.\n\n  1. Treatment with prior anti-PD-1 therapy must have continued for a minimum of 8 weeks\n  2. Patients who in the physician's judgement are not candidates for treatment with an anti-CTLA-4 antibody are eligible\n* Has documented BRAF V600 mutation status. Patients with BRAF mutation should have received prior BRAF-directed therapy (with or without a MEK inhibitor) prior to enrollment in the study, unless deemed not clinically indicated at Investigator's discretion due to concurrent medical condition or prior toxicity.\n* Has at least 1 measurable and injectable tumor of ≥1 cm in longest diameter (or shortest diameter for lymph nodes).\n* Has adequate hematologic function.\n* Has adequate hepatic function.\n* Has adequate renal function.\n* Prothrombin time (PT) ≤1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤1.5 × ULN\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1 for patients 18 years and older or a Lansky performance score (PSc) ≥80 for patients 12 to 17 years of age.\n* Life expectancy of at least 3 months.\n* Female and male patients of reproductive potential must agree to avoid becoming pregnant or impregnating a partner and adhere to highly effective contraception requirements during the treatment period and for at least 6 months after the last dose of study treatment.\n* Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) test within 72 hours before the first dose of study treatment.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Primary mucosal or uveal melanoma.\n* More than 2 lines of systemic therapy for advanced melanoma.\n* Known acute or chronic hepatitis.\n* Known human immunodeficiency virus (HIV) infection.\n* Active significant herpetic infections or prior complications of HSV-1 infection.\n* Had systemic infection requiring IV antibiotics or other serious active infection requiring antimicrobial, antiviral, or antifungal treatment within 14 days prior to dosing.\n* With active significant herpetic infections or prior complications of HSV-1 infection.\n* Evidence of spinal cord compression or at high risk of spinal cord compression.\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis at time of screening.\n* Serum lactate dehydrogenase (LDH) >2 × ULN.\n* Major surgery ≤2 weeks prior to starting study drug.\n* Prior malignancy active within the previous 3 years, except for locally curable cancers that have apparently been cured\n* History of significant cardiac disease including myocarditis or congestive heart.\n* History of life-threatening toxicity related to prior immune.\n* Active, known, or suspected autoimmune disease requiring systemic treatment.\n* History of (noninfectious) pneumonitis that required steroids or has current pneumonitis.\n* Prior oncolytic virus or other therapy given by intratumoral administration.\n* Requires intermittent or chronic use of systemic (oral or IV) antivirals with known antiherpetic activity (eg, acyclovir).\n* Has received a live vaccine within 28 days prior to the first dose of study treatment.\n* Systemic anticancer therapies within 5 half-lives or 4 weeks of the first dose, whichever is shorter.\n* Conditions requiring treatment with immunosuppressive doses (>10 mg per day of prednisone or equivalent) of systemic corticosteroids other than for corticosteroid replacement therapy within 14 days after enrollment.",
    "miscellaneous_criteria": "Key"
}